Altamira Therapeutics Ltd.
CYTOF Healthcare Biotechnology
Altamira Therapeutics Ltd.’s revenue for fiscal 2022 (year ended December 2022) was $320,300.00.
Follow CYTOF
Altamira Therapeutics Ltd. (CYTOF) Altman Z-score
Altamira Therapeutics Ltd.'s Altman Z-score for fiscal 2022 is −60.32, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2022 | −60.32 | (46.32) |
| FY2021 | −13.99 | — |
How fiscal 2022’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (1.76) | — | −2.12 | |
| Retained earnings / total assets | (31.96) | — | −44.74 | |
| EBIT / total assets | (4.15) | — | −13.68 | |
| Market value of equity / total liabilities | 0.29 | — | 0.17 | |
| Sales / total assets | 0.05 | — | 0.05 | |
| Altman Z-score | Distress zone | −60.32 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −144.21 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| BPTH Bio-Path Holdings, Inc. compare | 6.9× |
| MLEC Moolec Science SA compare | −1.9× |
| SPRC SciSparc Ltd. compare | −18.7× |
| CYTOF Altamira Therapeutics Ltd. | −60.3× |
| CRIS Curis, Inc. compare | −87.8× |
| BBLG Bone Biologics Corp. compare | — |
| PTIX Atrinsic Inc. compare | — |
| ZVSA ZyVersa Therapeutics, Inc. compare | — |
| MNTRQ 9 Meters Biopharma, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets